B
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Bart Barlogie's research focuses on the molecular and temporal evolution of multiple myeloma, investigating the pathways from precursor conditions to advanced disease states. His work delves into the genetic and molecular characteristics that drive myeloma progression, including the identification of gene signatures that predict the risk of monoclonal gammopathy of undetermined significance (MGUS) progressing to multiple myeloma. Barlogie has also examined the spatial architecture of myeloma and its microenvironment at the single-cell level, contributing to a deeper understanding of disease heterogeneity.
Further research areas include the development of prognostic scoring systems, such as the individualized and weighted Myeloma Prognostic Score System (MPSS), to improve patient risk stratification. His investigations extend to the biological mechanisms underlying myeloma, including the role of specific genes like CST6 in suppressing osteolytic bone disease. Barlogie also contributes to research on the feasibility and risk factors associated with outpatient stem cell transplantation for multiple myeloma.
With a distinguished publication record, including 1154 total publications and over 76,000 citations, Barlogie is recognized as a highly cited researcher. He maintains collaborations with colleagues at the University of Arkansas for Medical Sciences, including Maurizio Zangari, Sharmilan Thanendrarajan, John D. Shaughnessy, and Carolina Schinke, with whom he has co-authored numerous publications.
Metrics
- h-index: 138
- Publications: 1154
- Citations: 76,293
Selected Publications
-
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)
-
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)
-
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma (2024)
-
Development and validation of an individualized and weighted Myeloma Prognostic Score System (<scp>MPSS</scp>) in patients with newly diagnosed multiple myeloma (2024)
-
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023)
-
Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211 (2023)
-
Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma (2023)
-
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level (2023)
-
A gene signature can predict risk of MGUS progressing to multiple myeloma (2023)
-
Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols. (2023)
-
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states (2022)
-
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation (2022)
-
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission (2022)
-
N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma (2021)
-
High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse (2021)
Collaboration Network
Top Collaborators
Maurizio Zangari
University of Arkansas for Medical Sciences
14 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
Showing 5 of 14 shared publications
Frits van Rhee
University of Arkansas for Medical Sciences
14 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Development and validation of an individualized and weighted Myeloma Prognostic Score System (<scp>MPSS</scp>) in patients with newly diagnosed multiple myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
Showing 5 of 14 shared publications
Carolina Schinke
University of Arkansas for Medical Sciences
13 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
Showing 5 of 13 shared publications
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
12 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 12 shared publications
John D. Shaughnessy
University of Arkansas for Medical Sciences
9 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Development and validation of an individualized and weighted Myeloma Prognostic Score System (<scp>MPSS</scp>) in patients with newly diagnosed multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- PHF19 inhibition as a therapeutic target in multiple myeloma
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
Showing 5 of 9 shared publications
Cody Ashby
Winthrop Rockefeller Foundation
7 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse
Showing 5 of 7 shared publications
Fenghuang Zhan
University of Arkansas for Medical Sciences
7 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Development and validation of an individualized and weighted Myeloma Prognostic Score System (<scp>MPSS</scp>) in patients with newly diagnosed multiple myeloma
- PHF19 inhibition as a therapeutic target in multiple myeloma
- Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma
Showing 5 of 7 shared publications
Brian A. Walker
Indiana University – Purdue University Indianapolis (US)
6 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse
- PHF19 inhibition as a therapeutic target in multiple myeloma
- Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups
Showing 5 of 6 shared publications
Guido Tricot
University of Arkansas for Medical Sciences
6 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma
Showing 5 of 6 shared publications
Clyde Bailey
University of Arkansas for Medical Sciences
6 shared publications
In database
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma
Showing 5 of 6 shared publications
Samer Al Hadidi
University of Arkansas for Medical Sciences
6 shared publications
In database
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma
Showing 5 of 6 shared publications
Faith E. Davies
NYU Langone Health (US)
5 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse
- Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups
- N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma
Gareth J. Morgan
NYU Langone Health (US)
5 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse
- Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups
- N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma
Eileen M. Boyle
NYU Langone Health (US)
4 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse
- PHF19 inhibition as a therapeutic target in multiple myeloma
- Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups
Michael Bauer
University of Arkansas for Medical Sciences
4 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse
- Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups
Similar Researchers
Based on overlapping research topics
John D. Shaughnessy
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Gene expression and cancer classification
Yongzhong Yuan
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Hematopoietic Stem Cell Transplantation
Cancer Genomics and Diagnostics
Manojna Konda
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Hematopoietic Stem Cell Transplantation
Fenghuang Zhan
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Bone health and treatments
Amani Erra
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Hematopoietic Stem Cell Transplantation
B Barlogie
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Hematopoietic Stem Cell Transplantation